Kymera Therapeutics KYMR
NASDAQ KYMR
$111.79 +1.28 (+1.16%)
At close: Sep 30, 2026 · 4:00 PM EDT

Kymera Therapeutics (KYMR) EBITDA Margin (2019 - 2026)

Updated

Kymera Therapeutics (KYMR) posted EBITDA Margin of -113.20% for Q2 2026, up 605.46 percentage points from -718.66% a year earlier and up 125.80 percentage points from the prior quarter.

Analysis

Kymera Therapeutics (KYMR) EBITDA Margin (2019 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, EBITDA Margin at Kymera Therapeutics was -325.67%, up 353.71 percentage points year-over-year; for FY2025, it came in at -869.87%, down 329.72 percentage points from FY2024.

  • Annual EBITDA Margin shows a five-year change of -739.00 percentage points (FY2020 to FY2025).
  • In prior years, Kymera Therapeutics' EBITDA Margin was -540.16% in FY2024 (-334.07 pp), -206.08% in FY2023 (+131.93 pp), -338.02% in FY2022 (-203.28 pp) and -134.74% in FY2021 (-3.87 pp).
  • The Q2 2026 figure stands as the highest quarterly EBITDA Margin since Q4 2023.
  • On a year-over-year basis, EBITDA Margin increased in three of the last eight quarters, with an average year-over-year change of -623.40 percentage points.
  • The strongest year-over-year quarter for EBITDA Margin in the past five years was Q2 2026, with a gain of 605.46 percentage points; the weakest was Q4 2025, with a drop of 2274.91 percentage points.
  • According to Business Quant data, EBITDA Margin for the three prior quarters was -239.00% (Q1 2026), -3340.21% (Q4 2025) and -3269.61% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 35.95%
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 49.01%
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 6.02%
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn -
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 33.11%
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 46.01%
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn -124.26%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn 39.10%
10 Kymera Therapeutics 9.15 Bn 6.45 Bn - -113.20%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -113.20%
Mar 31, 2026 -239.00%
Dec 31, 2025 -3,340.21%
Sep 30, 2025 -3,269.61%
Jun 30, 2025 -718.66%
Mar 31, 2025 -327.50%
Dec 31, 2024 -1,065.30%
Sep 30, 2024 -1,874.82%
Jun 30, 2024 -190.98%
Mar 31, 2024 -547.97%
Dec 31, 2023 -38.47%
Sep 30, 2023 -1,197.42%
Jun 30, 2023 -257.27%
Mar 31, 2023 -469.54%
Dec 31, 2022 -234.29%
Sep 30, 2022 -461.89%
Jun 30, 2022 -348.32%
Mar 31, 2022 -376.70%
Dec 31, 2021 -218.04%
Sep 30, 2021 -137.52%
API Access

Kymera Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=KYMR&period=max&api_key=YOUR_API_KEY